miR-22 promotes HBV-related hepatocellular carcinoma development in males

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5593-5603

  Jiang, Runqiu ^a   Deng, Lei ^a   Zhao, Liang ^a   Li, Xiangcheng ^a   Zhang, Feng ^a   Xia, Yongxiang ^a   Gao, Yun ^a   Wang, Xuehao ^a   Sun, Beicheng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MICRORNA; MICRORNA 22; MYELOID DIFFERENTIATION FACTOR 88; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TISSUE; CARCINOMA CELL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B VIRUS; HUMANS; INTERLEUKIN-1ALPHA; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED ICR; MICRORNAS; RECEPTORS, INTERLEUKIN-1; RNA, MESSENGER; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION;

EID: 80052447492     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1734     Document Type: Article

References (34)

1. Bortolami M., Kotsafti A., Cardin R., Farinati F. Fas/FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat 2008;15:515-522 (Pubitemid 351798989)
2. Hirankarn N., Kimkong I., Kummee P., Tangkijvanich P., Poovorawan Y. Interleukin-1beta gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. World J Gastroenterol 2006;12:776-779 (Pubitemid 43380763)
3. Hundsberger H., Verin A., Wiesner C., Pfluger M., Dulebo A., Schutt W., et al. TNF: a moonlighting protein at the interface between cancer and infection. Front Biosci 2008;13:5374-5386
4. Nakagawa H., Maeda S., Yoshida H., Tateishi R., Masuzaki R., Ohki T., et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 2009;125:2264-2269
5. Sakamoto T., Higaki Y., Hara M., Ichiba M., Horita M., Mizuta T., et al. Interaction between interleukin-1beta -31T/C gene polymorphism and drinking and smoking habits on the risk of hepatocellular carcinoma among Japanese.Cancer Lett 2008;271:98-104.
6. Wong V.W., Yu J., Cheng A.S., Wong G.L., Chan H.Y., Chu E.S., et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009;124:2766-2770
7. Sun B., Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 2008;27:6228-6244
8. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436 (Pubitemid 44050137)
9. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-227
10. Sakurai T., Maeda S., Chang L., Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A 2006;103:10544-10551 (Pubitemid 44078014)
11. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121-124 (Pubitemid 47056470)
12. Sakurai T., He G., Matsuzawa A., Yu G.Y., Maeda S., Hardiman G., et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008;14:156-165
13. Jiang R., Xia Y., Li J., Deng L., Zhao L., Shi J., et al. High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer. Int J Cancer 2009;126:1263-1274
14. Shenoy K., Wu Y., Pervaiz S. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res 2009;69:1941-1950
15. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol 2008;48:380-381
16. Kang S.C., Lee B.M. DNA methylation of estrogen receptor alpha gene by phthalates. J Toxicol Environ Health A 2005;68:1995-2003.
17. Kim M.J., White-Cross J.A., Shen L., Issa J.P., Rashid A. Hypomethylation of long interspersed nuclear element-1 in hepatocellular carcinomas. Mod Pathol 2009;22:442-449
18. Villa E., Colantoni A., Grottola A., Ferretti I., Buttafoco P., Bertani H., et al. Variant estrogen receptors and their role in liver disease. Mol Cell Endocrinol 2002;193:65-69 (Pubitemid 34823608)
19. Adams B.D., Furneaux H., White B.A. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007;21:1132-1147 (Pubitemid 46984764)
20. Liu W.H., Yeh S.H., Lu C.C., Yu S.L., Chen H.Y., Lin C.Y., et al. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 2009;136:683-693
21. Zhao J.J., Lin J., Yang H., Kong W., He L., Ma X., et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008;283:31079-31086
22. Pandey D.P., Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol 2009;29:3783-3790
23. Yang Y.F., Tan D.M., Xie Y.T., Zhao W., Hou Z.H., Zhong Y.D. Mycophenolate mofetil prevents lethal acute liver failure in mice induced by bacille Calmette-Guerin and lipopolysaccharide. J Gastroenterol Hepatol 2008;23:611-618 (Pubitemid 351501145)
24. Falleti E., Fabris C., Toniutto P., Fontanini E., Cussigh A., Bitetto D., et al. Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology 2009;77:304-313
25. Jacques A., Bleau C., Turbide C., Beauchemin N., Lamontagne L. Macrophage interleukin-6 and tumour necrosis factor-alpha are induced by coronavirus fixation to Toll-like receptor 2/heparan sulphate receptors but not carcinoembryonic cell adhesion antigen 1a. Immunology 2009;128:e181-e192
26. Krishnan J., Selvarajoo K., Tsuchiya M., Lee G., Choi S. Toll-like receptor signal transduction. Exp Mol Med 2007;39:421-438 (Pubitemid 47443856)
27. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009;9:57-63.
28. Chen C.J., Kono H., Golenbock D., Reed G., Akira S., Rock K.L. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007;13:851-856 (Pubitemid 47038190)
29. Elkon K.B. IL-1alpha responds to necrotic cell death. Nat Med 2007;13:778-780 (Pubitemid 47038177)
30. Singer C.F., Kronsteiner N., Hudelist G., Marton E., Walter I., Kubista M., et al. Interleukin 1 system and sex steroid receptor expression in human breast cancer: Interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res 2003;9:4877-4883 (Pubitemid 37323293)
31. Zhang J., Yang Y., Yang T., Liu Y., Li A., Fu S., et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer 2010;103:1215-1220
32. Hagemann T., Biswas S.K., Lawrence T., Sica A., Lewis C.E. Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood 2009;113:3139-3146
33. Mauro C., Zazzeroni F., Papa S., Bubici C., Franzoso G. The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity. Methods Mol Biol 2009;512:169-207.
34. Muriel P. NF-kappaB in liver diseases: a target for drug therapy. J Appl Toxicol 2009;29:91-100.